I think what this really highlight for me is a maturing in the commercial relationship between UniQuest and ResApp. UniQuest could just as easily have tried to partner with a new entity for the new tech (some businesses would view that as spreading risk), but have instead elected to take an established route to market.
It's clear to me that UniQuest are very, very pleased with the work ResApp has undertaken to date to commercialise Smartcough, and whats more have seen sense in partnering with a known quantity to get this new tech to market.
Great relationship unfolding here folks. UniQuest really is the golden goose that has the potential to keep on laying. It's up to TK and the team to be the preferred egg catchers.
Ann: RAP Licenses Additional Pneumonia Diagnostic from UniQuest, page-25
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #